Proposed $1.2bn move was under scrutiny by competition watchdogs in the UK and US
Two of the world’s major DNA sequencing equipment companies have agreed to terminate a takeover agreement in the wake of probes by competition authorities.
Both the UK’s Competition and Markets Authority and the United States Federal Trade Commission (FTC) had raised concerns about the impact on scientists of a deal between Illumina and Pacific Biosciences.
This article on Research Professional News is only available to Research Professional or Pivot-RP users.
Research Professional users can log in and view the article via this link
Pivot-RP users can log in and view the article via this link.